![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1399716
¼¼°èÀÇ °Ëü äÃë Ä«µå ½ÃÀå : Á¦Ç°º°, °Ëüº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, ¿¹Ãø(2023-2032³â)Specimen Collection Cards Market - By Product (Cotton & Cellulose-based, Fiber-based), Specimen (Blood, Saliva, Urine), Application (Infectious Disease Testing, Newborn Screening), End-use - Global Forecast, 2023-2032 |
¼¼°è °Ëü äÃë Ä«µå ½ÃÀå ±Ô¸ð´Â 2023-2032³â µ¿¾È CAGR 5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
°Ëü äÃë Ä«µå´Â °Ëü äÃë, ¿î¼Û ¹× º¸°üÀ» °£¼ÒÈÇÏ¿© Áø´Ü ÇÁ·Î¼¼½º¸¦ °£¼ÒÈÇÏ´Â ±â´ÉÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ÀÌ´Â ½Å¼ÓÇϰí Á¤È®ÇÑ °Ëü äÃë°¡ Àû½Ã¿¡ Áø´Ü°ú Ä¡·á¿¡ ÇʼöÀûÀÎ ÀÇ·á ºÐ¾ß¿¡¼ ƯÈ÷ Áß¿äÇÕ´Ï´Ù.
ÀÌ Á¦Ç°Àº ºÐÀÚ °Ë»ç¸¦ À§ÇÑ DNA, RNA ¹× ´Ü¹éÁú º¸Á¸¿¡ Àû¿ëµÇ¾î ¿¬±¸ ¹× Áø´Ü ½ÇÇè½Ç¿¡ ÇʼöÀûÀÎ Á¦Ç°À¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ Áúº´¿¡ ´ëÇÑ ºÐÀÚ Áø´Ü ±â¼úÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÏ¸é¼ ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. 2022³â 6¿ù, »ý¹°ÇÐÀû ¿¬±¸¸¦ À§ÇÑ ¿Ïº®ÇÑ ½Ã·á º¸È£ÀÇ ¼±µÎÁÖÀÚÀÎ GenTegra LLC´Â ÀÚ»çÀÇ Á¦Ç°±º Áß ÃֽŠRNA ¾ÈÁ¤È Á¦Ç°ÀÎ RNAdvantage¸¦ Ãâ½ÃÇÏ¿´½À´Ï´Ù. À̹ø Ãâ½Ã·Î GenTegra Á¦Ç°Àº ½Å¼±ÇÑ Á¶Á÷ »ùÇà ¹× Á¤Á¦µÈ ¾×ü RNAÀÇ ±ÍÁßÇÑ RNA¸¦ ¾ÈÁ¤È ¹× º¸È£ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.
¼¼°è °Ëü äÃë Ä«µå »ê¾÷Àº Á¦Ç° À¯Çü, °Ëü À¯Çü, ¿ëµµ, ÃÖÁ¾ ¿ëµµ, Áö¿ªº°·Î ±¸ºÐµË´Ï´Ù.
¼¶À¯ ±â¹Ý ºÎ¹®Àº ½Ã·á º¸°ü ¹× ¿î¼ÛÀÇ ÀåÁ¡À¸·Î ÀÎÇØ 2032³â±îÁö °·ÂÇÑ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Ä«µå´Â ½Ã·á º¸Á¸À» À§ÇÑ ¾ÈÁ¤ÀûÀΠȯ°æÀ» Á¦°øÇÏ¿© ÇÙ»ê ºÐÇØ¸¦ ¹æÁöÇÏ°í »ý¹°ÇÐÀû ½Ã·áÀÇ ¹«°á¼ºÀ» º¸ÀåÇÕ´Ï´Ù. ¶ÇÇÑ, ¼¶À¯ ±â¹Ý Àç·áÀÇ È¯°æ Ä£ÈÀûÀΠƯ¼ºÀº Áö¼Ó°¡´ÉÇÏ°í »ýºÐÇØ °¡´ÉÇÑ Á¦Ç°¿¡ ´ëÇÑ °Á¶¿Í ÀÏÄ¡ÇÏ¿© Á¦Ç° ¼ö¿ä¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
¼Òº¯ ºÐ¾ß´Â »ùÇà äÃëÀÇ ÆíÀǼº°ú ºñħ½À¼ºÀ¸·Î ÀÎÇØ 2023³âºÎÅÍ 2032³â±îÁö ´«¿¡ ¶ç´Â ¼ºÀåÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼Òº¯ »ùÇÃÀ» À§ÇØ ¼³°èµÈ Ä«µå´Â Àü¹® Àåºñ³ª ħ½ÀÀû ÀýÂ÷ ¾øÀ̵µ ½Ã·á¸¦ äÃëÇÏ°í º¸°üÇÒ ¼ö ÀÖ´Â °£ÆíÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÆíÀǼºÀº ¾à¹° °Ë»ç, ÀӽŠ°Ë»ç, Áúº´ ¸ð´ÏÅ͸µ µî ´Ù¾çÇÑ Áø´Ü ºÐ¾ß¿¡¼ ƯÈ÷ ¸Å·ÂÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ »ç¿ë ÆíÀǼºÀº ¼Òº¯ »ùÇÃÀ» Àå±â°£ ¾ÈÁ¤ÀûÀ¸·Î º¸°üÇÒ ¼ö ÀÖ´Â ´É·Â°ú °áÇÕÇÏ¿© °Ëü äÃë Ä«µåÀÇ »ç¿ë¿¡ À¯¸®ÇÏ°Ô ÀÛ¿ëÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
À¯·´ÀÇ °Ëü äÃë Ä«µå »ê¾÷ ±Ô¸ð´Â ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó 2023-2032³â »çÀÌ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·á ¹× ºÐÀÚ Áø´ÜÀÇ ¹ßÀüÀº ƯÈ÷ À¯Àüü ¹× °¨¿°¼º Áúȯ °Ë»ç µîÀÇ ºÐ¾ß¿¡¼ Á¦Ç° ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. À¯·´ ÇコÄÉ¾î ºÐ¾ßÀÇ ¾ö°ÝÇÑ ±ÔÁ¦¿Í ǰÁú ±âÁØÀº ½Å·ÚÇÒ ¼ö ÀÖ°í Ç¥ÁØÈµÈ ½Ã·á äÃë ¹æ¹ýÀÇ Á߿伺À» °Á¶Çϸç ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
Specimen Collection Cards Market is estimated to observe 5% CAGR from 2023 to 2032, driven by increasing emphasis on efficient diagnostic procedures. Specimen collection cards, with their ability to simplify sample collection, transport, and storage, contribute to streamlined diagnostic processes. This is particularly crucial in healthcare settings where quick and accurate sample collection is essential for timely diagnosis and treatment.
The product finds application in preserving DNA, RNA, or proteins for molecular testing, making it indispensable in research and diagnostic laboratories. The growing adoption of molecular diagnostic techniques for various diseases fuels the market demand. In June 2022, GenTegra LLC, a leader of complete sample protection for biological research, launched RNAdvantage, the latest RNA stabilization products in their suite. With this launch, GenTegra products can stabilize and protect valuable RNA in fresh tissue samples and purified liquid RNA.
The worldwide specimen collection cards industry is segmented based on product type, specimen type, application, end-use, and region.
Fiber-based segment is anticipated to gain momentum and grow at a strong CAGR through 2032, owing to its advantages in sample preservation and transportation. These cards provide a stable environment for specimen storage, preventing degradation of nucleic acids and ensuring the integrity of biological samples. Additionally, the eco-friendly nature of fiber-based materials aligns with the increasing emphasis on sustainable and biodegradable products, contributing to the product demand.
Urine segment will record notable growth during 2023 and 2032, due to the convenience and non-invasive nature in sample collection. The cards designed for urine samples provide a user-friendly method for collecting and preserving specimens without the need for specialized equipment or invasive procedures. This simplicity makes them particularly attractive in various diagnostic applications, including drug testing, pregnancy testing, and disease monitoring. The ease of use, coupled with the ability to stabilize urine samples for extended periods, will favor the usage of specimen collection cards.
Europe specimen collection cards industry size will witness significant growth throughout 2023 and 2032, backed by the increasing prevalence of chronic diseases and the rising focus on preventive healthcare. The advancements in personalized medicine and molecular diagnostics further fuel the product demand, especially in applications including genomics and infectious disease testing. Stringent regulations and quality standards in the European healthcare sector underscore the importance of reliable and standardized sample collection methods, stimulating the regional market growth.